I-Mab
NASDAQ:IMAB

Watchlist Manager
I-Mab Logo
I-Mab
NASDAQ:IMAB
Watchlist
Price: 0.9397 USD -2.01% Market Closed
Market Cap: 76m USD
Have any thoughts about
I-Mab?
Write Note

I-Mab
Total Current Liabilities

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

I-Mab
Total Current Liabilities Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Total Current Liabilities CAGR 3Y CAGR 5Y CAGR 10Y
I-Mab
NASDAQ:IMAB
Total Current Liabilities
ÂĄ411.8m
CAGR 3-Years
-11%
CAGR 5-Years
4%
CAGR 10-Years
N/A
Beigene Ltd
HKEX:6160
Total Current Liabilities
ÂĄ12.8B
CAGR 3-Years
22%
CAGR 5-Years
50%
CAGR 10-Years
N/A
Beijing Wantai Biological Pharmacy Enterprise Co Ltd
SSE:603392
Total Current Liabilities
ÂĄ2.7B
CAGR 3-Years
48%
CAGR 5-Years
51%
CAGR 10-Years
N/A
Shanghai RAAS Blood Products Co Ltd
SZSE:002252
Total Current Liabilities
ÂĄ1.6B
CAGR 3-Years
27%
CAGR 5-Years
41%
CAGR 10-Years
32%
Chongqing Zhifei Biological Products Co Ltd
SZSE:300122
Total Current Liabilities
ÂĄ22.7B
CAGR 3-Years
32%
CAGR 5-Years
39%
CAGR 10-Years
68%
Imeik Technology Development Co Ltd
SZSE:300896
Total Current Liabilities
ÂĄ297.7m
CAGR 3-Years
49%
CAGR 5-Years
46%
CAGR 10-Years
N/A
No Stocks Found

I-Mab
Glance View

Market Cap
76m USD
Industry
Biotechnology

I-Mab operates as a clinical stage biopharmaceutical company. The company is headquartered in Shanghai, Shanghai. The company went IPO on 2020-01-17.

IMAB Intrinsic Value
0.7454 USD
Overvaluation 21%
Intrinsic Value
Price

See Also

What is I-Mab's Total Current Liabilities?
Total Current Liabilities
411.8m CNY

Based on the financial report for Dec 31, 2023, I-Mab's Total Current Liabilities amounts to 411.8m CNY.

What is I-Mab's Total Current Liabilities growth rate?
Total Current Liabilities CAGR 5Y
4%

Over the last year, the Total Current Liabilities growth was -46%. The average annual Total Current Liabilities growth rates for I-Mab have been -11% over the past three years , 4% over the past five years .

Back to Top